BioSpace News Archive

Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop the next generation of leaders in healthcare data sciences.

Karius, a life sciences company that delivers genomic insights for infectious diseases, announced new findings that show the potential clinical utility of its Karius® Test to detect pathogens causing serious infections using a simple blood draw.

Leveraging data from world’s largest electronic veterinary health records database, Banfield discovers osteoarthritis in pets is on the rise alongside pet obesity

Leveraging advanced artificial intelligence and sensor technology, Walabot HOME now offers an unprecedented level of accuracy when detecting falls, further eliminating the need for wearables and pendants.

N8 Medical, a clinical-stage company focused on developing innovative anti-infective and anti-inflammatory solutions, today announced the appointment of industry veteran Marc Rohman as Chief Executive Officer and Board member effective June 1st, 2019.

PatientPoint® and the National Comprehensive Cancer Network® (NCCN®) today announced a new collaboration to integrate the NCCN Guidelines for Patients®: Nausea and Vomiting into the PatientPoint® Interact™ Exam Room Program.

Voice assistant comprehension study in Nature Digital Medicine reveals platforms’ pain points and calls for the need to improve accuracy of voice technology for health

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QIAGEN Clinical Insight (QCI®), its clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has achieved a milestone of more than 1 million patient test cases analyzed and interpreted.

Accreditations demonstrate high quality offered to payers, patients and prescribers

DURECT Corporation announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock of the Company at a price per share of $0.52.